

MedStar Health, Inc.

POLICY AND PROCEDURE MANUAL

Policy Number: MP.128.MH
Last Review Date: 02/21/2019
Effective Date: 01/01/2019

MP.128.MH – Thyroid Nodule Molecular Testing

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar CareFirst PPO

MedStar Health considers **Thyroid Nodule Molecular Testing** medically necessary for the following indications:

The following indications for molecular testing of thyroid FNA samples are based on the Bethesda Reporting System of Thyroid Cytology. Molecular testing of thyroid FNA samples is indicated for those members who meet both of the following criteria:

1. Member has been diagnosed with a thyroid nodule
2. Cytological diagnosis of the thyroid FNA sample must be classified as indeterminate under any one of the following categories;
 - a. AUS/FLUS
 - b. FN/SFN
 - c. SMC

Limitations

Molecular testing of thyroid FNA samples is not generally indicated and/or covered when FNA cytology diagnosis is benign or malignant. Exceptions to this may be made on a case by case basis by requesting prior authorization and documenting medical necessity.

Background

The American Cancer Society estimates that for thyroid cancer in the United States for 2015 there will be about 62,450 new cases of thyroid cancer and 1,950 deaths from thyroid cancer. A thyroid ultrasound is used to detect small thyroid nodules, discrete masses present in the thyroid gland. Fine-needle aspiration (FNA) is used to evaluate the nodules to exam for any benign lesions or malignant tumors.

The National Cancer Institute provides an overview on thyroid cancer and its four types: papillary, follicular, medullary, and anaplastic thyroid cancer. Papillary thyroid cancer is the most common type of thyroid cancer. Certain genetic conditions such as familial medullary thyroid cancer, multiple endocrine neoplasia type 2A syndrome and multiple

MP.128.MH – Thyroid Nodule Molecular Testing

Policy Number: MP.128.MH
Last Review Date: 02/21/2019
Effective Date: 01/01/2019

endocrine neoplasia type 2B syndrome are identified risks known to increase the risk of thyroid cancer.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
CPT Codes	
81210	BRAF
81275-81276	KRAS codons 12 & 13
81401	PAX/PPARG
81403	HRAS exon 2; KRAS exon 3, codon 61
81404	NRAS exon 1 & 2; RET common variants
The following code(s) require prior authorization:	
81479	Unlisted molecular pathology procedure (PIK3CA, Guanine Nucleotide-binding Protein, TSHR, RET/PTC 1 Translocation, RET/PTC 3 Translocation, PTEN gene known fam var)
ICD-10 codes covered if selection criteria are met:	
C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland
E01.2	Iodine-deficiency related (endemic) goiter, unspecified
E04.0-E04.9	Other nontoxic goiter
R22.0	Localized swelling, mass and lump, head
R22.1	Localized swelling, mass and lump, neck

References

1. American Cancer Society. What are the key statistics about thyroid cancer? [Internet]. American Cancer Society. Last Medical Review: 02/24/2014. Last Revised: 03/17/2015. Accessed: 10/27/2015.
<http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-key-statistics>
2. American Thyroid Association. Thyroid Nodules [Internet]. ©2019 American Thyroid Association. Published: 5/4/2012. <http://www.thyroid.org/what-are-thyroid-nodules/>
3. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD). LCD No. L35396 - Biomarkers for Oncology. (Contractor:

MP.128.MH – Thyroid Nodule Molecular Testing

Policy Number: MP.128.MH

Last Review Date: 02/21/2019

Effective Date: 01/01/2019

Novitas Solutions, Inc.). Revision Effective Date: 10/04/2018.

<https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35396&ver=162&Date=01%2f14%2f2019&DocID=L35396&bc=iAAAABAAAA&>

4. Cooper DS, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2009;19(11):
<http://www.thyca.org/download/document/409/DTCguidelines.pdf>
5. Hayes Genetic Test Evaluation Report. miRInform Thyroid. Annual Review March 6, 2015. Archived March 17, 2016.
6. Hayes Genetic Test Evaluation Report. Afirma Thyroid FNA Analysis. Annual Review February 10, 2015. Last Updated October 19, 2017.
7. Kim M, Kim EK, Park S, et al. US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. *Radiographics* 2008 Nov-Dec; 28(7):1869-1886 discussion 1887. doi: 10.1148/rg.287085033 Accessed: 1/30/2019. <http://radiographics.rsna.org/content/28/7/1869.full>
8. Kouniavsky G, Zeiger MA. The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. *J Surg Oncol*. 2012 Apr 1;105(5):438-443. doi: 10.1002/jso.21935.
<http://www.ncbi.nlm.nih.gov/pubmed/22441894>
9. Kouniavsky G, Zeiger MA. The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. *J Surg Oncol*. 2012 Apr 1;105(5):438-443. doi: 10.1002/jso.21935.
<http://www.ncbi.nlm.nih.gov/pubmed/22441894>
10. National Institute of Health: National Cancer Institute. Thyroid Cancer [Internet]. Accessed: 01/30/2019. <http://www.cancer.gov/cancertopics/types/thyroid>
11. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metab*. 2011 Nov; 96(11):3390-3397 <https://www.ncbi.nlm.nih.gov/pubmed/21880806>
12. Nikiforov YE, Yip L, Nikiforova MN. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. *Clin Cancer Res*. 2013 May 1;19(9):2283-2288. doi: 10.1158/1078-0432.CCR-12-1253. Epub 2013 Feb 19.
<http://www.ncbi.nlm.nih.gov/pubmed/23422095>
13. U.S. Cancer Statistics Working Group. *United States Cancer Statistics: 1999–2010 Incidence and Mortality Web-based Report*. [Internet] Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Accessed: 1/30/2019.
<https://nccd.cdc.gov/uscs/toptencancers.aspx>
14. Witt RL, Ferris RL, Pribitkin EA, et al. Diagnosis and management of differentiated thyroid cancer using molecular biology. *Laryngoscope*. 2013

MP.128.MH – Thyroid Nodule Molecular Testing

Policy Number: MP.128.MH

Last Review Date: 02/21/2019

Effective Date: 01/01/2019

Apr;123(4):1059-1064. doi: 10.1002/lary.23838. Epub 2013 Feb 12. Review.
<http://www.ncbi.nlm.nih.gov/pubmed/23404751>

Disclaimer:

MedStar Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of MedStar Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

MedStar Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.